EU Module 1 eCTD Specification
Version 3.0
October 2015
## Change Record

<table>
<thead>
<tr>
<th>Version</th>
<th>Date</th>
<th>Author(s)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1</td>
<td>July, 2001</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.2</td>
<td>September, 2001</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.3</td>
<td>October, 2001</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.4</td>
<td>November, 2001</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.5</td>
<td>February, 2002</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.6</td>
<td>February, 2002</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.7</td>
<td>March, 2002</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.8</td>
<td>October, 2002</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.9</td>
<td>November, 2002</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.91</td>
<td>February, 2003</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.92</td>
<td>July, 2003</td>
<td>Stan van Belkum</td>
<td>Draft</td>
</tr>
<tr>
<td>0.93</td>
<td>February 2004</td>
<td>M. Bley</td>
<td>Draft</td>
</tr>
<tr>
<td>0.95.1</td>
<td>May 2004</td>
<td>EMEA</td>
<td>Draft</td>
</tr>
<tr>
<td>0.95.2</td>
<td>28 May 2004</td>
<td>EMEA</td>
<td>Draft</td>
</tr>
<tr>
<td>0.95.3</td>
<td>23 June 2004</td>
<td>EMEA</td>
<td>Draft</td>
</tr>
<tr>
<td>1.0</td>
<td>July 2004</td>
<td>EMEA</td>
<td>Final</td>
</tr>
<tr>
<td>1.1</td>
<td>December 2005</td>
<td>EMEA</td>
<td>Integration of PIM</td>
</tr>
<tr>
<td>1.2</td>
<td>May 2006</td>
<td>EMEA</td>
<td>Structural changes from CTD</td>
</tr>
<tr>
<td>1.2.1</td>
<td>October 2006</td>
<td>EMEA</td>
<td>Alignment to CTD and Change Requests</td>
</tr>
<tr>
<td>1.3</td>
<td>May 2008</td>
<td>EMEA</td>
<td>Incorporation of paediatric requirements and Change Requests</td>
</tr>
<tr>
<td>1.4</td>
<td>August 2009</td>
<td>EMEA</td>
<td>Alignment to the New Variation Regulation and Change Requests</td>
</tr>
<tr>
<td>1.4.1</td>
<td>November 2011</td>
<td>EMA</td>
<td>Incorporation of Additional Change Requests and Q&amp;A</td>
</tr>
<tr>
<td>1.4.2</td>
<td>December 2012</td>
<td>EMA</td>
<td>New Draft version including proposed DTD changes as requested by: CR 20120924 rev CR 20121119 CR 20091203 CR 20100408 CR 20101022-01 CR 20101214 CR 20110614</td>
</tr>
<tr>
<td>1.4.3</td>
<td>17 December 2012</td>
<td>EFPIA</td>
<td>EFPIA changes, added PDF 1.5, 1.6, edited file allowed formats, added common for CP, adjustments to agency codes</td>
</tr>
<tr>
<td>1.4.4</td>
<td>20 December 2012</td>
<td>EFPIA</td>
<td>Removed PIM, added HR to App 2.4, updated Spanish agency name in 2.4, removed ‘AR’ from App 2 codes, {p24}, added –var to tracking table name, updated TOC</td>
</tr>
<tr>
<td>1.4.5</td>
<td>21 December 2012</td>
<td>M BLEY</td>
<td>Acceptable file formats in EU Module 1 (XML), use of « common » as country sub-directory for CAP, further examples of filenaming convention</td>
</tr>
<tr>
<td>2.0</td>
<td>27 February 2013</td>
<td>EFPIA/EMA/NCA/M BLEY</td>
<td>All accepted change requests implemented</td>
</tr>
<tr>
<td>2.1</td>
<td>30.05.2015</td>
<td>K. Menges</td>
<td>Implementing accepted change requests: Update of agencies names, additional submission types, adding submission unit types and related term list, alignment of term lists with respective ETUCT CTL, additional samples and adjusting examples according to the above mentioned changes, adding EDQM to the list of receivers</td>
</tr>
<tr>
<td>2.2</td>
<td>02.07.2015</td>
<td>A. J. Nixon</td>
<td>Modifications to improve consistency and English wording</td>
</tr>
<tr>
<td>2.3</td>
<td>10.07.2015</td>
<td>K. Menges</td>
<td>Incorporating comments from eSub CMB, TEAB, HHMG in regard to additional explanations of technical aspects of the UUID, additional submission</td>
</tr>
<tr>
<td>Date</td>
<td>Author</td>
<td>Comments and Actions</td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>29.09.2015</td>
<td>K. Menges</td>
<td>Reconciliation of comments from public consultation.</td>
<td></td>
</tr>
<tr>
<td>01.10.2015</td>
<td>K. Menges</td>
<td>Additional submission type 'rup', change of definition of submission unit type 'consolidating'</td>
<td></td>
</tr>
<tr>
<td>07.10.2015</td>
<td>K. Menges</td>
<td>Preparation of the clean version 3.0</td>
<td></td>
</tr>
</tbody>
</table>
## Reviewers

<table>
<thead>
<tr>
<th>Version</th>
<th>Name</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.1-0.3</td>
<td>EU Regulators</td>
<td>EU Regulatory Authorities, EMEA</td>
</tr>
<tr>
<td>0.4</td>
<td>Interested parties</td>
<td></td>
</tr>
<tr>
<td>0.5-0.6</td>
<td>EU Regulators</td>
<td>EU Regulatory Authorities, EMEA</td>
</tr>
<tr>
<td>0.7-0.8</td>
<td>Interested parties</td>
<td></td>
</tr>
<tr>
<td>0.9</td>
<td>EU regulators</td>
<td>EU Regulatory Authorities, EMEA</td>
</tr>
<tr>
<td>0.91</td>
<td>EU Regulators ICH, EMEA</td>
<td>EU Regulatory Authorities, EMEA</td>
</tr>
<tr>
<td>0.92</td>
<td>EU regulators</td>
<td>EU Regulatory Authorities (members TiGes and NtA)</td>
</tr>
<tr>
<td>0.95.1</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>0.95.2</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>0.95.3</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>1.1</td>
<td>EU regulators</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>1.2</td>
<td>EU regulators</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>1.3</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>1.4</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>1.4.1</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>1.4.3</td>
<td>December 2012 EFPIA</td>
<td>EFPIA Review of EMA changes</td>
</tr>
<tr>
<td>2.0</td>
<td>EU Regulators, interested parties</td>
<td>EU Regulatory Authorities (members TiGes and NtA), EFPIA, Pharma, other interested parties</td>
</tr>
<tr>
<td>2.1.5</td>
<td>eSubmission CMB</td>
<td>EU Regulatory Authorities (NCAs and EMA), EFPIA, EGA, other interested parties</td>
</tr>
<tr>
<td>2.1.5</td>
<td>TEAB</td>
<td>Telematic Enterprise Architecture Board (NCAs and EMA)</td>
</tr>
<tr>
<td>2.1.5</td>
<td>IT Directors</td>
<td>IT Directors of all NCAs</td>
</tr>
<tr>
<td>2.4</td>
<td>EU-Regulators, interested parties</td>
<td>Public consultation</td>
</tr>
<tr>
<td>2.4.1</td>
<td>EU-Regulators, interested parties</td>
<td>Review of reconciliation changes</td>
</tr>
</tbody>
</table>
# TABLE OF CONTENT

**DOCUMENT CONTROL** ......................................................................................................................... 2

- **CHANGE RECORD** ......................................................................................................................... 2
- **REVIEWERS** .................................................................................................................................. 4

**GLOSSARY OF TERMS** ................................................................................................................................. 6

**INTRODUCTION** ..................................................................................................................................... 7

**EU MODULE 1: REGIONAL INFORMATION** ........................................................................................ 7

**REGIONAL FILE FORMATS** .................................................................................................................... 7

- **Module 1** ......................................................................................................................................... 7
- **Modules 2 to 5** .............................................................................................................................. 8

**USE OF ELECTRONIC SIGNATURES** ....................................................................................................... 8

**HANDLING OF EMPTY OR MISSING ECTD SECTIONS** ........................................................................ 8

**UPDATING BACKBONE ATTRIBUTES/METADATA** .................................................................................. 9

**GENERAL ARCHITECTURE OF MODULE 1** ........................................................................................ 9

- **Envelope** .......................................................................................................................................... 9
- **M-1-EU** ........................................................................................................................................... 10
- **Directory / File Structure** ............................................................................................................... 10
- **Node Extensions** ............................................................................................................................ 11
- **File Naming Convention** ................................................................................................................ 11
- **Folder and File Name Path Length** ................................................................................................ 12

**BUSINESS PROTOCOL** .......................................................................................................................... 12

**UNIVERSAL UNIQUE IDENTIFIER** ...................................................................................................... 13

**CHANGE CONTROL** ............................................................................................................................. 13

**APPENDIX 1: THE EU MODULE 1 XML SUBMISSION** ........................................................................ 14

- **Appendix 1.1: Envelope Element Description** ............................................................................... 14
- **Appendix 1.2: Country-Specific Elements** ..................................................................................... 27
- **Appendix 1.3: Product Information Element Description** ............................................................... 28

**APPENDIX 2: DIRECTORY / FILE STRUCTURE FOR MODULE 1** ....................................................... 29

- **Appendix 2.1: Destination Codes** .................................................................................................. 46
- **Appendix 2.2: Language Codes** ...................................................................................................... 47
- **Appendix 2.3: SPC, Labelling and Package Leaflet File Name Identifiers** ..................................... 47
- **Appendix 2.4: Agency Codes and Names** ...................................................................................... 48

**APPENDIX 3: MODULARISED DTD FOR EU MODULE 1** ................................................................... 50

- **EU-REGIONAL.DTD** ..................................................................................................................... 51
- **EU-ENVELOPE.MOD** ..................................................................................................................... 56
- **EU-LEAF.MOD** ............................................................................................................................... 59
## Glossary of Terms

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Applicant</td>
<td>A pharmaceutical company or its agent that is submitting information in support of an <em>application</em>.</td>
</tr>
<tr>
<td>Applicant’s Information</td>
<td>Regulatory information submitted by an <em>applicant</em> for, or to maintain, a marketing authorisation that falls within the scope of this guidance document.</td>
</tr>
<tr>
<td>eCTD application or also known as a dossier</td>
<td>A collection of electronic documents compiled by a pharmaceutical company or its agent in compliance with European legislation and guidelines in order to seek a marketing authorisation or any amendments thereof. An <em>eCTD application</em> may comprise a number of <em>regulatory activities</em>. In the EU an eCTD application may comprise several dosage forms and strengths, all under one invented product name. This is understood to be equivalent to a Global Marketing Authorisation according to Art. 6 para 2 Dir. 2001/83/EC as amended.</td>
</tr>
<tr>
<td>Procedure</td>
<td>A Community registration procedure for the authorisation of medicinal products in the European Community. There are 4 types of procedure that operate within the EC – Centralised, Decentralised, Mutual Recognition and National.</td>
</tr>
<tr>
<td>Regulatory Activity</td>
<td>A <em>single sequence or a collection of sequences</em> covering the start to the end of a specific business process, e.g. an MA application or Type II variation. To allow a more precise handling, the regulatory activity will be classified using a controlled vocabulary (submission type or regulatory activity type) and a free text field for a short narrative description.</td>
</tr>
<tr>
<td>Sequence</td>
<td>A single set of information and / or electronic documents submitted at one particular time by the applicant as a part of, or the complete application. Any collection of content assembled in accordance with the eCTD specification (ICH and EU) will be described using metadata as defined by the EU envelope. Sequences may be related to one another within one regulatory activity. The related sequence number should always be stated. In case of activities with only one sequence the same sequence number will be used.</td>
</tr>
<tr>
<td>Submission Type</td>
<td>The submission type describes the <em>regulatory activity</em> to which the content will be submitted.</td>
</tr>
<tr>
<td>Submission Unit Type</td>
<td>The submission unit type element of the envelope metadata set describes the content at a lower level (a “sub-activity”) which is submitted in relation to a defined regulatory activity such as the initial submission, the applicant response to validation issues or list of questions or any other additional information.</td>
</tr>
</tbody>
</table>
Introduction

This document specifies Module 1 of the electronic Common Technical Document (eCTD) for the European Union ("EU").

This document should be read together with the ICH eCTD Specification to prepare a valid eCTD submission in the EU. The latest version of the ICH eCTD Specification can be found at: http://estri.ich.org/eCTD.

EU Module 1: Regional Information

The ICH Common Technical Document ("CTD") specifies that Module 1 should contain region-specific administrative and product information. The content and numbering of Module 1 for the EU is specified in the latest version of the Notice to Applicants that can be found at: http://ec.europa.eu/health/documents/eudralex/vol-2/index_en.htm

The following items listed in the Notice to Applicants should be included for an initial submission:

- a cover letter,
- a comprehensive table of contents\(^1\),
- an application form,
- product information documents,
- information on the experts,
- specific requirements for different types of applications (if required),
- an environmental risk assessment,
- information relating to orphan market exclusivity (if required),
- information relating to pharmacovigilance,
- information relating to clinical trials (if required),
- information relating to paediatrics.

In addition, other items such as answers to regulatory questions, rationale for variations and renewal documentation could also be included in Module 1.

It should be noted, that for subsequent submissions in the lifecycle of a medicinal product, e.g. for a variation, not all of the above mentioned types of document need to be included in Module 1. Consult the various legal documents for guidance on the exact documents to be submitted in such a case.

This document describes only the region-specific information that is common to all submissions in the different Member States. However, at the same time the EU Module 1 Specification allows for country-specific information to be included in Module 1, if required. Country-specific information could relate to the details of the business process applied (e.g. specifying the number and names of those parts for which a paper copy is still requested) and local preferences for file formats.

The acronym ‘EMEA’ will remain in use in the Product Numbers, however it has been updated to EMA in the various technical texts.

Regional File Formats

Module 1

The file formats that can be included in Module 1 are given in Table 1. In addition to the common format PDF, as defined by the ICH eCTD Specification Document, XML and image formats are also accepted on an ad hoc basis. Note that all PDF files included in an eCTD (irrespective of the module) should be v1.4, v1.5, v1.6 or v1.7 (see ICH Q&A for further detail re PDF version acceptability), except where there is an agency-specific requirement for a later version (e.g. for an application form).

\(^1\) TOC not required for eCTD as the XML backbone acts as a table of contents
Although the use of the file formats defined in Table 1 are mandatory, regulatory authorities and applicants could agree on the use of other formats for Module 1 content provided outside of the eCTD in the working-documents folder. For example, proprietary format MS Word is requested by some agencies for Product Information documents in Section 1.3. These documents, if requested, should not be referenced in the eCTD backbone, and should normally be provided in addition to the PDF versions (Note: Track changed Product Information provided in Word format is not required to be provided in PDF format within the eCTD. An exception to this rule is in the provision of either product labelling or risk management plan documentation in the Centralised Procedure, where the tracked changes version of the document in PDF format should be placed inside the eCTD, alongside the clean, non-tracked version.). Guidance should be referred to regarding the provision of MS Word and other requested documents (e.g. the Harmonised Technical Guidance for eCTD Submissions in the EU).

Table 1 Acceptable file formats for Module 1

<table>
<thead>
<tr>
<th>Document</th>
<th>File Format</th>
<th>Remark</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cover letter</td>
<td>PDF</td>
<td>PDF preferably generated from electronic source.</td>
</tr>
<tr>
<td>Administrative forms:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Variation application form incl. background for the variation</td>
<td>PDF</td>
<td></td>
</tr>
<tr>
<td>• Renewal form and its annexes</td>
<td>PDF</td>
<td></td>
</tr>
<tr>
<td>Product Information:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>• Product information text*</td>
<td>PDF</td>
<td>PDF preferably generated from electronic source. If a higher resolution is necessary for the mock-ups, use JPEG, GIF, PNG or SVG on a case-by-case basis.</td>
</tr>
<tr>
<td>• Packaging mock-ups</td>
<td>PDF</td>
<td></td>
</tr>
<tr>
<td>• Reference to specimens</td>
<td>PDF</td>
<td></td>
</tr>
<tr>
<td>Other</td>
<td>PDF</td>
<td>PDF preferably generated from electronic source.</td>
</tr>
</tbody>
</table>

* = SmPC, Package Leaflet and labelling

**Modules 2 to 5**

No additional file formats are defined for Modules 2 to 5 other than those mentioned in the ICH eCTD Specification Document.

**Use of Electronic Signatures**

As the use of digital signatures for electronic submissions within the EU is not fully supported some agencies continue to request wet signed documents and others will accept the log-in credentials for portals as a sufficient authentication. For details, please refer to the Harmonised Technical Guidance for eCTD Submissions in the EU.

**Handling of Empty or Missing eCTD Sections**

Detailed statements justifying the absence of data or specific CTD sections should be provided in either the cover letter or respective Module 2 documents. Placeholder documents highlighting ‘no relevant content’ should not be included in the eCTD. These files would create a document lifecycle for non-existent documents, and unnecessary complication and maintenance of the eCTD lifecycle.
The EU Module 1 is provided with a standard style-sheet that can be used to view the content. Note that the style-sheet has been designed to display the complete Module 1 table of contents (i.e. all the sections), irrespective of whether files are actually present in those sections or not.

**Updating backbone attributes/metadata**

It is not possible to update XML backbone attributes such as ‘manufacturer’ during the eCTD lifecycle, nor is it necessary to attempt workarounds such as deleting existing documents and resubmitting them with new attributes. The recommendation is to retain the obsolete entry and to rely on the document content to explain the current details.

Whilst the need for a change to the set of EU Module 1 XML attributes/metadata (this covers country, language and product information type) in the middle of the procedure is deemed to be very rare, it is recommended to contact the agency whether such change could be done during the procedure, along with other changes, or as part of an eCTD “reformat” submission.

**General Architecture of Module 1**

The EU Module 1 architecture is similar to that of Modules 2 to 5 of the eCTD, comprising a directory structure and a backbone with leaves. The backbone must be a valid XML document according to the EU Regional Document Type Definition (DTD). The backbone instance (the “eu-regional.xml” file) contains meta-data for the leaves, including pointers to the files in the directory structure. In addition, the EU Regional DTD defines meta-data at the submission level in the form of an envelope. The root element is “eu-backbone” and contains two elements: “eu-envelope” and “m1-eu”.

The EU Regional DTD is modularised, i.e. the envelope and leaves are referenced from the main part of the DTD as external entities called respectively “eu-envelope.mod” and “eu-leaf.mod”. The EU “leaf” is identical to the leaf element described in the ICH eCTD DTD; reference is made to Table 6-8 of the ICH eCTD Specification. A full description of the EU Regional DTD can be found in Appendix 3 of this specification.

Examples of XML coding for a simple new application, specific regulatory activities and a submission for a National or Mutual Recognition Procedure are provided as an annex to this specification. Examples of XML coding that support the new variation regulation are provided as well.

Files can be referred to across modules (e.g. from Module 1 to Module 2) or across sequences within the same eCTD application; note however that it is not possible to refer to files in sequences in other eCTD applications. When referring to files across modules or across sequences, the reference must always be relative, starting from the location of the XML file. For instance, a reference from within Module 1 of Sequence 0003 (e.g. 0003/m1/eu-eu-regional.xml) to a file located in Module 2 of Sequence 0000 (e.g. file “introduction.pdf” in folder 0000/m2/22-intro), would be encoded in the EU Module 1 as “../../../0000/m2/22-intro/introduction.pdf”. (This example is not business-specific – it merely serves to demonstrate the principle).

**Envelope**

The “eu-envelope” element is designed to be used for all types of submissions (MAAs, variations, renewals, etc.) for a given medicinal product and will mainly be used for the first simple processing at the agency level. The envelope provides meta-data at the eCTD application and sequence level. A description of each “envelope” element is provided in Appendix 1 of this specification.

For Centralised Procedure submissions, the “eu-envelope” element should contain a single “envelope” element with the country attribute value set to ‘EU-EMA’. For all other procedures, the “eu-envelope” element should contain a separate “envelope” element for each Member State involved in the procedure that is going to receive that particular sequence, and each envelope country attribute should be set to the country value of the receiving Member State. Note that the value ‘common’ cannot be used in the envelope.
The envelope element submission ‘mode’ should only be used in variation, extension and workshare regulatory activities, and the value can be set to: ‘single’, ‘grouping’ or ‘worksharing’ (see examples in Appendix 1.1). An additional high-level submission number should also be provided in the envelope under the following circumstances:

- For worksharing submissions including PSUSA
  Here, the submission ‘mode’ value will be ‘worksharing’ and the high-level number is a worksharing number;

- For submissions of grouped Type 1A variations that affect multiple marketing authorisations
  Here, the submission ‘mode’ will be ‘grouping’ and the high-level number is group number/report’ number. Please refer to the annex and associated guidance for further details of this high-level number. Examples of ‘single’, ‘grouping’ and ‘worksharing’ submissions are provided in the annex to this specification.

Such a high-level number, if appropriate, should be provided in addition to the usual product-specific procedure tracking numbers. If the high-level number is required but is not known (e.g., for the first submission of the procedure), this element should be populated with the value ‘to be advised’. The relevant number will usually be provided by or obtained from the appropriate tracking system or regulatory agency. In the case of Centralised Procedure this number is always available on the Eligibility Confirmation Letter as ‘Product Reference’. E.g. if the Eligibility Confirmation Letter indicates Product number H0002227 please eliminate first digit (0) from H0002227 to reflect H002227 in the envelope. The use of Product Number H/C/xxxxxxx is applicable after the Initial MAA has been submitted to the EMA.

In the case of Centralised Procedure, it is strongly recommended that when applying for a variation and the procedure number has not yet been allocated, then the term ‘to be advised’ should be used. If the content of a sequence pertains to more than one submission type (e.g., parallel variations) the highest variation type should be selected as submission type. In this case there will be more than one related sequence. The value of submission unit type will be dictated by the content, e.g., “response”.

For submissions to EDQM, the agency name EU-EDQM and the submission type ‘CEP application’ need to be selected. The submission unit type should be used as appropriate.

**m1-eu**
The “m1-eu” element of the EU regional DTD is based on the same conceptual approach as the common part of the ICH eCTD DTD. It provides an XML catalogue with meta-data at the leaf level including pointers to the location of files in a directory structure. As for the ICH eCTD DTD, the “m1-eu” element maps to the directory structure. (There may at times be what is seen to be an apparently ‘redundant’ directory structure, but this is necessary in order to be able to use the same file / directory structure for all procedures.) Furthermore, as the same structure will be used during the lifecycle of the submission, the use of country directories even to place a single file in one submission is justified because it could be used to house several files in a subsequent submission, and in doing so the structure would not change. A tabular overview of the directory structure explaining where to place country and language-specific files is provided in Appendix 2 of this specification.

**Directory / File Structure**
The EU Module 1 Specification provides a directory and file structure that is strongly recommended:

- The same high-level directory structure is used for all 4 procedures (MR, National, Decentralised and Centralised Procedures). This is possible, despite the fact that files for the MR, Decentralised and National Procedures are usually country-specific, whereas files for the Centralised Procedure are usually language-specific.
- Country directories are named according to Appendix 2.1.
- Language directories are named according to Appendix 2.2.
- The recommended directory structure for the use of country and language identifiers is described in Appendix 2. In general, Modules 1.0, 1.2, 1.3.2, 1.3.3, 1.3.4, 1.3.5, ‘Additional
Data’ and ‘Responses’ have country subdirectories. Module 1.3.1 (Product Information) has both country and language subdirectories.

- For the Centralised Procedure, the country subdirectory is always named either "ema" or "common", irrespective of whether it contains "common" or country folders; language subdirectories in Module 1.3.1 have the appropriate language identifier.
- For Mutual Recognition, Decentralised and National Procedures:
  - Documents for each country are placed in an appropriately named subdirectory. The folder name "common" should only be used for documents potentially applicable to all EU countries, irrespective of whether they are currently involved in the procedure or not.
  - In Module 1.3.1, every document should be placed in an appropriately named language subdirectory, even if the country only has one official language. Where a country has more than one official language (e.g. Belgium) separate language subdirectories should be used for each set of documents in a different language.
  - Should a country have documents in more than one language in a Module other than 1.3.1, then it is recommended to use the VAR (variable) part of the filename to identify the language of the document.

**Node Extensions**

Node extensions are a way of providing extra organisational information to the eCTD. The node extension should be visualised as an extra heading in the CTD structure and should be displayed as such when the XML backbone is viewed.

However, the use of node extensions should be limited to those areas where it is critical. Consideration should be given regarding the impact of the view for the reviewer since the inconsistent use of node extensions can lead to unanticipated effects in the cumulative view of a submission.

The following rules govern the use of node extensions in the EU:

- Node extensions must not be used where ICH-specified sub-headings already exist (e.g. indication, manufacturer, drug substance, drug product are all-ICH specified node extensions).
- Node extensions must only be used at the lowest level of the eCTD structure (e.g. a node extension can be used at the level 5.3.5.1 but must not be used at the level 5.3).
- Node extensions are mainly to be used to group together documents made up of multiple leaf elements (e.g. a clinical study made up of separate files for the synopsis, main body and individual appendices could be grouped together under a node extension with the Study Identifier as its Title attribute).
- Node extensions must be maintained over the entire life of the eCTD lifecycle (e.g. if a node extension is used in Sequence 0000 to group files for a study report in Module 5.3.5.1, then any files submitted in a later sequence must also be placed under a node extension, even if only one file is submitted).
- Node extensions may be nested as this is allowed by the eCTD DTD. However, as noted in Bullet 2, the first node extension must be at the lowest level in the eCTD structure (e.g. in Module 5.3.7 a node extension may be added to group together files with the Study Identifier as Title attribute). Further node extensions may be added as children of the Study Identifier node, separating CRFs from individual patient listings.
- The content associated with a node extension can be placed in a separate sub folder in the submission; this is recommended for studies in Module 5 where study reports are provided as multiple files. However, there is no specific requirement for an additional subfolder. For example, if node extensions are used to further define ‘m1-responses’, additional folders under ‘m1/eu/responses/cc’ are not recommended. Instead, navigational support the variable part of the file name can be used as outlined in the next section.

**File Naming Convention**

File names in Module 1 follow one of two conventions.
Country-specific items in sections 1.0; 1.2; 1.3; m1-responses and m1-additional-data have the general structure CC-FIXED-VAR.EXT, where CC is a country code used in some CTD modules, FIXED is a defined component of the filename based on the CTD section and VAR is an additional optional variable component. EXT represents the file extension. Components are separated by a hyphen (except the dot for the file extension). No spaces should be used within each component but hyphens can be used in the variable part to separate several words.

Fixed components are highly recommended. The variable component is optional and should be used as appropriate to further define these files. The variable component, if used, should be a meaningful concatenation of words with the option of hyphens for separators and should be kept as brief and descriptive as possible. File extensions in line with this specification should be applied as applicable.

The first component in a file name should be the country code, as per Appendix 2.1, except when the document is valid for all countries in all procedures, as per Appendix 2. The second component should be the document type code, as per Appendix 2 and 2.3. The third component if necessary should be the variable component. In cases where differentiation is needed (e.g. between 1.5mg and 15mg) the word ‘point’ written in full (i.e. ‘1point5mg’) or a hyphen can be used (i.e.’1-5mg’).

There are no recommendations for variable components in this specification. The format of the file is indicated by the file extension. File names should always be in lowercase, in line with the ICH eCTD specification.

Examples:
- fr-cover.pdf
- be-form.xml
- it-form-annex1.pdf
- pt-form-proofpayment.pdf
- uk-outer-tablet10mg.pdf
- ema-combined-tablet1-5mg.pdf
- ema-combined-tablet10mgannotated.pdf
- nongmo.pdf

In m1-responses/cc, the recommendation is to use cc-responses-&lt;regulatory activity type identifier&gt;-&lt;timeline identifier&gt;-&lt;content identifier&gt;.pdf, using the -var component of the filename to define the content. It is recommended to use the variable component of the filename and the leaf title, to present the information clearly to the assessor.

Examples:
- common-responses-maa-d106-clin.pdf Leaf title: Day 106 Clinical Responses, MAA
- common-responses-var05-d59-qual.pdf Leaf title: Day 59 Quality Responses, Var 05

Non-country specific items in Sections 1.4; 1.5; 1.6; 1.7; 1.8; 1.9 and 1.10 have fixed file names, as defined in Appendix 2.

Folder and File Name Path Length
The overall folder and file name path length starting from the sequence number should not exceed 180 characters, for any file in any module. This is an EU regional requirement, and it is acknowledged that this is less than the ICH agreed overall path length.

Business Protocol
It is clear that the detailed business process between industry and a regulatory agency in the EU cannot be completely harmonised due to the differences in organisation and processes. The exact description has to be provided by the EMA, EDQM or the individual Member States. However, a few common steps can be identified and will be detailed in the Harmonised Technical Guidance for eCTD
Submissions in the EU. The EDOM and most national agencies are unable to provide positive feedback of technically valid submissions. However, if there is any problem experienced during the upload of the sequence, agencies will promptly inform the applicants. Please note that the EMA provides automated feedback (acknowledgement) of technical validation for submissions received via their eSubmission Gateway and Web Client.

Universal Unique Identifier

In the EU, although the eCTD envelope contains several pieces of information about the eCTD application that the sequence belongs to, such as the procedure number and the trade name, there have been instances when an eCTD sequence has been loaded into the wrong application by the receiving agency. For this reason, all eCTD sequences built in accordance with this revised specification must contain a universal unique identifier (UUID), linking the sequence to the eCTD application to which it belongs.

The applicant should generate a UUID based on ISO/IEC 11578:1996 and ITU-T Rec X.667 | ISO/IEC 9834-8:2005. It is a hexadecimal number in the form of xxxxxxxx-xxxx-xxxx-xxxx-xxxxxxxxxxxx, showing 32 digits and 4 hyphens. The ‘x’ will be replaced by a number or a letter. Creating with uppercases or lowercases is not restricted. It is recommended to use randomly generated sections (version 4 of UUID types). Such UUID is represented for example as: 4cc86cf0-9088-4a3c-9526-fa6320f4c469 or 31E96E01-D593-4943-8956-C5BD1334A842.

This structure guarantees uniqueness across applicants and application. The UUID will be generated for the first time when creating the first sequence following this version of the specification, and will be provided in the eCTD envelope. All subsequent sequences for that same application will contain the same UUID. In this way, sequences can be allocated automatically to the correct eCTD application by the receiving agency. The UUID will be transferred to a new MAH and will remain the same also in cases the procedure number changes due to an RMS change. Any independent application with its own life cycle should have its own UUID, e.g. CEP applications or referrals not within an existing application. In contrast, redacted clinical study reports or post authorisation measures will relate to an existing application of which the UUID need to be used.

The backbones of previously submitted sequences do not contain the UUID and do not need updating. However, any eCTD sequence created using this revised specification must have a UUID, and this will be tested with the relevant validation criteria.

Change Control

The EU Module 1 specification is likely to change with time. Factors that could affect the content of the specification include, but are not limited to:

- Change in the content of the Module 1 for the CTD, either through the amendment of information, at the same level of detail, or by provision of more detailed definition of content and structure
- Change to the regional requirements for applications that are outside the scope of the CTD
- Update of standards that are already in use within the eCTD
- Identification of new standards that provide additional value for the creation and/or usage of the eCTD
- Identification of new functional requirements
- Experience of use of the eCTD by all parties, in particular Module 1.

Details of the change control process and a current Electronic Submission Change Request/Q&A Form are available on the EU eSubmission website.
Appendix 1: The EU Module 1 XML Submission

The EU Module 1 XML Submission contains an element for each Table of Contents entry of the Notice to Applicants Module 1. The following sections describe information that is captured within the Module 1 XML submission in an eCTD, but which is not captured within the Notice to Applicants Table of Contents for Module 1.

Appendix 1.1: Envelope Element Description

The “eu-envelope” element is the root element that defines meta-data of the submission. This element may contain several envelope entries, each related to a specific country.

<table>
<thead>
<tr>
<th>Element</th>
<th>Attribute</th>
<th>Description/Instructions</th>
<th>Example</th>
<th>Constraint</th>
<th>Occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>eu-envelope</td>
<td></td>
<td>Root element that provides meta-data for the submission. This element may contain several envelopes, which are country specific.</td>
<td>N/A</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td>envelope</td>
<td></td>
<td>Parent element for the submission meta-data. This element must be country-specific or in the case of the Centralised Procedure, ‘ema’ and in the case of CEP applications ‘edqm’.</td>
<td>N/A</td>
<td>Mandatory</td>
<td>Repeatable</td>
</tr>
<tr>
<td>country</td>
<td></td>
<td>The country to which the envelope applies (or ‘ema’ or respectively ‘edqm’).</td>
<td>be</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td>identifier</td>
<td></td>
<td>A UUID as specified by ISO/IEC 11578:1996 and ITU-T Rec X.667</td>
<td>ISO/IEC 9834-8:2005. The same UUID will be used for all sequences of an eCTD application.</td>
<td>25635f23-a3a4-c4e0-b994-99c5f074960f596</td>
<td>Mandatory</td>
</tr>
<tr>
<td>submission</td>
<td></td>
<td>Provides administrative information associated with the submission.</td>
<td>N/A</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td>Element</td>
<td>Attribute</td>
<td>Description/Instructions</td>
<td>Example</td>
<td>Constraint</td>
<td>Occurrence</td>
</tr>
<tr>
<td>---------</td>
<td>-----------</td>
<td>--------------------------</td>
<td>---------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>type</td>
<td></td>
<td>The type of regulatory activity to which the content will be submitted. The following are the valid values:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ maa = Marketing Authorisation Application</td>
<td>var-type2</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ var-typela = Variation Type IA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ var-typelain = Variation Type IAIN</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ var-type1b = Variation Type IB</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ var-type2 = Variation Type II</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ var-nat = National variation (e.g. national variation to apply for a pack size that is already registered within an existing MRP/DCP authorisation)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ extension = Extension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ rup = Repeat Use Procedure in decentralised or mutual recognition procedures to include one or more additional member states</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ psur = Periodic Safety Update Report (PSUR) which should only be used for PSURs outside of the PSUSA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ rmp = Risk Management Plan (outside any procedure)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ renewal = Renewal (yearly or 5-yearly)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-sob = specific obligation related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-anx = annex II condition related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-meas = additional pharmacovigilance activity in the risk-management plan related to a post-authorisation measures (RMP) (e.g. interim results of imposed/non-imposed interventional/non-interventional clinical or nonclinical studies)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-leg = legally binding measure related to a post-authorisation measures</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-sda = cumulative review following a request originating from a PSUR or a signal evaluation related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-capa = Corrective Action/Preventive Action related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-p45 = paediatric submissions related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-p46 = paediatric submissions related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-paes = Submission of a post authorisation efficacy study</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pam-rec = recommendation related to a post-authorisation measures e.g. quality improvement related to a post-authorisation measure</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pass107n = Submission of a post authorisation safety study protocol (according article 107n)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>▪ pass107q = Submission of a post authorisation safety study report (according article 107q)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Element</td>
<td>Attribute</td>
<td>Description/Instructions</td>
<td>Example</td>
<td>Constraint</td>
<td>Occurrence</td>
</tr>
<tr>
<td>---------------</td>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------</td>
<td>------------</td>
</tr>
<tr>
<td>asmf</td>
<td></td>
<td>Active Substance Master File</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pmf</td>
<td></td>
<td>Plasma Master File</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-20</td>
<td></td>
<td>Referral under Article 20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-294</td>
<td></td>
<td>Referral under Article 29(4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-29p</td>
<td></td>
<td>Referral under Article 29 paediatric</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-30</td>
<td></td>
<td>Referral under Article 30</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-31</td>
<td></td>
<td>Referral under Article 31</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-35</td>
<td></td>
<td>Referral under Article 35</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-53</td>
<td></td>
<td>Referral under Article 53</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-107i</td>
<td></td>
<td>Referral under Article 107i</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-16c1c</td>
<td></td>
<td>Referral under Article 16c (1c)i</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>referral-16c4</td>
<td></td>
<td>Referral under Article 16c(4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>annual-reassessment</td>
<td></td>
<td>Annual Reassessment</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>usr</td>
<td></td>
<td>Urgent Safety Restriction</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clin-data-pub-rp</td>
<td></td>
<td>Clinical data for publication – Redacted Proposal</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>clin-data-pub-fv</td>
<td></td>
<td>Clinical data for publication – Final Version</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>paed-7-8-30</td>
<td></td>
<td>Paediatric submission related to a paediatric investigational plan according to article 7, 8 or 30 of the Regulation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>paed-29</td>
<td></td>
<td>Paediatric submission post approval once a paediatric investigational plan has been performed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>paed-45</td>
<td></td>
<td>Paediatric submission according to article 45 of the Regulation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>paed-46</td>
<td></td>
<td>Paediatric submission according to article 46 of the Regulation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>article-58</td>
<td></td>
<td>Article 58 (to be used for an initial application)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>notification-61-3</td>
<td></td>
<td>Notification 61(3)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>transfer-ma</td>
<td></td>
<td>Transfer of a marketing authorisation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>lifting-suspension</td>
<td></td>
<td>Lifting of a suspension</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>withdrawal</td>
<td></td>
<td>Withdrawal of a marketing authorisation in regard to a strength or form or entirely. This submission type shall not be used to withdraw a regulatory activity.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>cep</td>
<td></td>
<td>Submission that applies to an application on a Certificate of suitability CEP application (EDQM only).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>none</td>
<td></td>
<td>In the exceptional case of reformating the application no regulatory activity is allowed. Therefore, ‘none’ must be stated. The submission application unit will identify the sub-activity related to the product. In the submission description some information can be provided to e.g. highlight specific modules being reformatted.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N.B. Officially, Roman numerals are used for variations, e.g. Type IA, Type II – the elements must remain Arabic, however.
<table>
<thead>
<tr>
<th>Element</th>
<th>Attribute</th>
<th>Description/Instructions</th>
<th>Example</th>
<th>Constraint</th>
<th>Occurrence</th>
</tr>
</thead>
</table>
| mode         |           | The high-level handling of the information submitted as part of variation(s) and extension applications. The mode should only be used in variation or line extension regulatory activities and must be included in every sequence of that activity. The following are the valid values:  
  - **single** = a single regulatory activity (e.g. a Type II variation)  
  - **grouping** = a grouped activity (e.g. several variations grouped into a single submission, or a report of type IA variations applicable to one or more marketing authorisations)  
  - **worksharing** = an activity subject to a worksharing agreement (e.g. a Type II variation or a PSUSA applicable to one or more marketing authorisations)  
  This information should be identical with the information provided/ticked in the application form.                                                  | Single        | Optional (note that this element must be populated for sequences in variation and line extension activities)                                                                                                           | Unique     |
| number       |           | This is the high-level submission number, either a 'worksharing' number, or the high-level submission number to be used when grouping Type IA variations for multiple marketing authorisations  
  (Note that for submissions affecting multiple MAs, the 'xxxx' used in the submission number is a permanent placeholder, as a single product number cannot be provided).  
  If the Applicant did not obtain the sequential number from the relevant Authorities in advance of their application this field should be populated as "xxxx".  
  For centrally authorised products this number must always be obtained in advance by sending an email to PA-BUS@ema.europa.eu. | For worksharing: EMEA/H/xxxx/WS/001  
For grouped IAs: EMEA/H/C/xxxx/IG/xxxx | Optional      | Unique                                                                                                                                   |            |
<p>| procedure-tracking |           | Provides administrative information associated with the application.                                                                                                                                          | N/A          | Mandatory                                                                 | Unique     |</p>
<table>
<thead>
<tr>
<th>Element</th>
<th>Attribute</th>
<th>Description/Instructions</th>
<th>Example</th>
<th>Constraint</th>
<th>Occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>number</td>
<td></td>
<td>This is any number, used by an agency or the applicant to track the submission, in any procedure, in relation to a particular product. This could be one or more of the following:</td>
<td>See column left</td>
<td>Mandatory</td>
<td>Repeatable</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• an MRP/DCP number (e.g. DE/H/0126/001/MR),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• a national procedure number (e.g. 2131577),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• the EMA application number (e.g. EMEA/H/C/000123 or EMEA/H/C/000123/II/tba (to be advised), or in case of sequences after ‘initial’, (e.g. ‘response’ or ‘additional-info’), EMEA/H/C/000123/II/14),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• an authorisation or licence number, (e.g. EU/1/00/44/0003 – 0004),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• any other number used by an agency to track a submission, (e.g. FL01234/0003-0004)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• a number used by the applicant to manage the submission within their company (e.g. Pharmacompany123)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>There must be at least one tracking number identified from the regulators and, in addition, the applicant can choose to include an internal tracking number. In the case of Centralised Procedure, it is strongly recommended that when applying for a variation and the procedure number has not yet been allocated, then the term ‘to be advised’ should be used (no internal number from the applicant should be used).</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>It is suggested that if the procedure number has not yet been allocated by the agency then the term ‘to be advised’ should be used. Applicants should consult national guidance for further information.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In case of worksharing, or grouped type IA variations applying to more than one MA, a separate eCTD submission must be built for each MA covered by the variation. In the envelope of each of the eCTD submissions, the high-level submission number will be the same, but the individual tracking numbers listed here should be specific to the MA in question, e.g.:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For worksharing:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EMEA/H/C/000123/WS005/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>In case of PSUSA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• PSUSA/00xxxxxx/201xxx</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>For grouped type 1A variations across multiple MAs:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• EMEA/H/C/000123/IG003/</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Please ensure that these WS/IG numbers are always mentioned in the case of additional information or corrigendum otherwise the Agency might not be able to process your submission correctly.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Element</td>
<td>Attribute</td>
<td>Description/Instructions</td>
<td>Example</td>
<td>Constraint</td>
<td>Occurrence</td>
</tr>
<tr>
<td>-----------------</td>
<td>-----------</td>
<td>----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>---------</td>
<td>------------</td>
<td>------------</td>
</tr>
</tbody>
</table>
| submission-unit |           | Submission unit type describes the content at a lower level (a “sub-activity”) which is submitted in relation to a defined regulatory activity. The following are the valid values:  
  - initial = Initial submission to start any regulatory activity  
  - validation-response = For rectifying business validation issues.  
  - response = submission unit type that contains the response to any kind of question, validation issues out-standing information requested by the agency  
  - additional-info = Other additional Information (could include, for example, missing files) and should only be used, if validation-response or response is not suitable  
  - closing = submission unit type that provides the final documents in the centralised procedure following the decision of the European Commission  
  - consolidating = submission unit type that consolidates the application after several information in the MRP or DCP handled outside the eCTD but that need to be integrated thereafter to maintain the life cycle properly. This submission unit type should also be used when consolidating the dossier in as a result of withdrawing or rejecting a single regulatory activity (not in case of the withdrawal of the entire application).  
  - corrigendum = Correction to the published annexes in the centralised procedure (usually shortly after approval).  
  - reformat = Intended to support the reformatting of an existing submission application from any format to eCTD, i.e. a baseline eCTD submission containing no content change and which will not be subject to review (see example below). This type will always be used together with the submission type ‘none’ | response | Mandatory   | Unique     |
| applicant       |           | The name of the company submitting the eCTD.                                                                                                                                                                           | PharmaCompany Ltd. | Mandatory   | Unique     |
| agency          |           | Parent element for the identification of the receiving agency.                                                                                                                                                         | N/A     | Mandatory   | Unique     |
| code            |           | The identification of the receiving agency (see Appendix 2.4).                                                                                                                                                         | EU-EMA  | Mandatory   | Unique     |
| procedure       |           | Defines the procedure in use with the submission                                                                                                                                                                      | N/A     | Mandatory   | Unique     |
| type            |           | The type of procedure for the submission. The following are the valid values:  
  - centralised = Centralised Procedure  
  - national = National Procedure  
  - mutual-recognition = Mutual Recognition Procedure  
  - decentralised = Decentralised Procedure | Centralised | Mandatory   | Unique     |
<p>| invented-name   |           | The name of the medicinal product.                                                                                                                                                                                   | WonderPill | Mandatory   | Repeatable |</p>
<table>
<thead>
<tr>
<th>Element</th>
<th>Attribute</th>
<th>Description/Instructions</th>
<th>Example</th>
<th>Constraint</th>
<th>Occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>inn</td>
<td></td>
<td>International Non-proprietary Name, used to identify pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property. A non-proprietary name is also known as a generic name.</td>
<td>Pioglitazone hydrochloride</td>
<td>Optional</td>
<td>Repeatable</td>
</tr>
<tr>
<td>sequence</td>
<td></td>
<td>This is the sequence number of the submission – this should start at 0000 for the initial submission, and then increase incrementally with each subsequent submission related to the same product e.g. 0000, 0001, 0002, 0003 etc.</td>
<td>0000</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td>related-sequence</td>
<td></td>
<td>This is the sequence number of previous submission(s) to which this submission relates e.g. the responses to questions to a particular variation. In the case of submission unit types 'initial' and 'reformat' related sequence is identical to the sequence number.</td>
<td>0001 see also annex document</td>
<td>Mandatory</td>
<td>Repeatable</td>
</tr>
</tbody>
</table>
| submission-description |   | This element is used to provide a free text description of the submission. The list below provides additional examples for such a field:  
  ▪ For an MAA: Original MAA Application for <Product X> / Response to D120 LOQ  
  ▪ For a Type II variation: Please quote the scope of variation from the Application Form  
  ▪ For a Type IB variation: Please quote the scope of variation from the Application Form  
  ▪ For an Annual Reassessment submission: 4th AR submission for <Product X>  
  ▪ In case of a referral related submission: Referral under Article YY  
  ▪ Response to validation questions  
  ▪ Providing supplementary information  
  ▪ Dxxx translations | Response to D120 LOQ | Mandatory    | Unique     |
**Example of the use of the Related Sequence and the Submission Unit type elements**

The related-sequence element is used to identify sequences belonging to the same ‘regulatory activity’. A 'regulatory activity' is a logical unit of submission activity (e.g., a Type II Variation) with a defined start and end point (e.g. initial submission to final approval). In the eCTD world, this will consist of all the sequences that together make up the lifecycle of that particular ‘regulatory activity’. The Submission Unit type element describes the stage within the regulatory activity, such as initial, response, consolidating.

The related-sequence attribute should always be equal to the sequence number. When submitting lifecycle sequences within an existing activity, the related-sequence attribute should be populated with the sequence number the regulatory activity has been started with. The submission unit type should be populated with the respective term describing the content of the sequence to be filed at that point in time. See below for some illustrative examples.

It is generally expected that there is usually just one related sequence, but there are occasions where more than one related sequence should be provided: e.g. there are two post authorisation measures (sequence 0050 and sequence 0060) and a single response (sequence 0070) is produced that relates to both post authorisation measures. If more than one different category of activities (submission Types) are referred to (as related sequence), then the “highest category” should be used in the envelope attributes. If any of the related variations were grouped, then ‘grouping’ should be used. For any of the submission types (regulatory activities) an initial and any of the additional submission unit types can be used, e.g. ‘response’ in case of responses to list of questions or out-standing list of issues. The post authorisation measure may have an initial and additional-info submission unit type. The submission description may describe details if this content is related to e.g. an earlier defined obligation or to which day in the procedure the response is assigned to.

Special attention should be paid to the correct use of the related-sequence element when the regulatory activity is a variation that covers more than one Marketing Authorisation. An example is given in the Annex.

<table>
<thead>
<tr>
<th>Sequence</th>
<th>Submission description</th>
<th>Submission type</th>
<th>Related sequence</th>
<th>Submission unit type</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>0000</td>
<td>Original MAA application</td>
<td>maa</td>
<td>0000</td>
<td>initial</td>
<td>This is the beginning of a new regulatory activity and so the submission unit type is ‘initial’. The related sequence should never be used together with the submission unit type ‘initial’</td>
</tr>
<tr>
<td>0001</td>
<td>Day 121 Responses to questions on the original application</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
<td>This is a continuation of the regulatory activity ‘maa’ initiated in 0000 and so the related sequence points to the beginning of that activity. The submission unit type describes the actual contribution ‘response’ being submitted within maa regulatory activity</td>
</tr>
<tr>
<td>0002</td>
<td>Day 181 Responses to further questions on the original application</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
<td>This is a continuation of the regulatory activity ‘maa’ initiated in 0000 and so the related sequence points to the beginning of that activity. The submission unit type describes the actual contribution ‘response’ being submitted within maa regulatory activity</td>
</tr>
<tr>
<td>0003</td>
<td>Letter of Undertaking (submission unit type: additional info)</td>
<td>maa</td>
<td>0000</td>
<td>additional-info</td>
<td>This is a continuation of the regulatory activity initiated in 0000 and so the related sequence points to the beginning of that activity. The submission unit describes the actual contribution ‘additional-info’ being</td>
</tr>
<tr>
<td></td>
<td>Submitted within maA regulatory activity</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>----------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0004</td>
<td><strong>Type II variation for ‘Treatment of Pain’ indication</strong> &lt;br&gt;var-type2 0004 initial &lt;br&gt;This is the beginning of a new regulatory activity ‘var-type2’ and so the submission unit is ‘initial’. The related sequence will be identical with the sequence number 0004.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0005</td>
<td><strong>Type II variation for a change in manufacturing site (Westferry)</strong> &lt;br&gt;var-type2 0005 initial &lt;br&gt;This is the beginning of another new regulatory activity ‘var-type2’ and so the submission unit is ‘initial’. Again, the related sequence will be identical with the sequence number 0005.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0006</td>
<td><strong>Responses to questions on Type II variation for ‘Treatment of Pain’ indication</strong> &lt;br&gt;var-type2 0004 response &lt;br&gt;This is a continuation of the regulatory activity initiated in 0004 and so the related sequence points to the beginning of that activity. The submission unit type ‘response’ indicates that this is a response to questions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0007</td>
<td><strong>Responses to questions on Type II variation for change in manufacturing site (Westferry)</strong> &lt;br&gt;var-type2 0005 response &lt;br&gt;As above, but this is a continuation of the regulatory activity initiated in 0005</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0008</td>
<td><strong>Extension to introduce a new dosage form (iv solution) that amends information provided in the original application and the manufacturing change variation</strong> &lt;br&gt;extension 0008 initial &lt;br&gt;This is the beginning of a new regulatory activity and so the submission unit type is ‘initial’. The related sequence will be identical with the sequence number 0008.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0009</td>
<td><strong>Updated, agreed, product information taking into account new indication (‘Treatment of Pain’)</strong> &lt;br&gt;var-type2 0004 response &lt;br&gt;This is the completion of the new indication (‘Treatment of Pain’) activity, the related sequence points to the sequence which was ‘initial’ for this activity, and submission unit indicates that this is a response to questions.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0010</td>
<td><strong>Updated, agreed product information for the iv formulation</strong> &lt;br&gt;extension 0008 consolidating or closing &lt;br&gt;This is the completion of the new dosage form (iv solution) extension, and so the related sequence is the sequence that started the activity. Submission unit type ‘consolidating’ indicates that further lifecycle ‘fixes’ have been applied in the sequence. If only the final product information text version will be submitted the submission unit type ‘closing’ will be more adequate.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

For a new regulatory activity, the appropriate submission type should be used. Applicants should refer to the submission type descriptions in the EU Module 1 specification. For the submission unit type that initiates a regulatory activity the term ‘initial’ should always be used. For subsequent sequences within that regulatory activity the respective terms should be selected from the submission unit type values in the EU M1 specification. The related sequence will be maintained as another way to describe relationships and will be especially meaningful in case of parallel variations.
After the Regulatory Activity has concluded a consolidation of the application may be necessary as in the late phase of the procedure direct exchange of draft documents and interim communication has happened. Final decision, final assessment reports and final versions of the product information texts should be submitted within a consolidating sequence. If only the final product information text version is being submitted the submission unit type ‘closing’ should be chosen. The submission type ‘corrigendum’ should only be used in exceptional circumstances to correct information, typically for the product information annexes to be provided in the centralised procedure.

Tables 1, 2 and 3 provide examples of this convention.

Table 1: Example of a MAA in the Centralised Procedure

<table>
<thead>
<tr>
<th>Sequence number</th>
<th>Submission Description</th>
<th>Submission Type</th>
<th>Related Sequence</th>
<th>Submission Unit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0000</td>
<td>MAA</td>
<td>maa</td>
<td>0000</td>
<td>initial</td>
</tr>
<tr>
<td>0001</td>
<td>Validation update</td>
<td>maa</td>
<td>0000</td>
<td>validation-response</td>
</tr>
<tr>
<td>0002</td>
<td>Day 121 responses</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0003</td>
<td>Day 181 responses</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0004</td>
<td>Day 210 Agreed English product information</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0005</td>
<td>Day 215 – translated product information</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0006</td>
<td>Final translations of product information for Decision after closing the procedure</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0007</td>
<td>Correction of errors in Danish product information after Decision</td>
<td>maa</td>
<td>0000</td>
<td>corrigendum</td>
</tr>
</tbody>
</table>
Table 2: Example of a MAA in the Decentralised Procedure

<table>
<thead>
<tr>
<th>Sequence number</th>
<th>Submission Description</th>
<th>Submission Type</th>
<th>Related Sequence</th>
<th>Submission Unit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0000</td>
<td>MAA</td>
<td>maa</td>
<td>0000</td>
<td>initial</td>
</tr>
<tr>
<td>0001</td>
<td>Validation update</td>
<td>maa</td>
<td>0000</td>
<td>validation-response</td>
</tr>
<tr>
<td>0002</td>
<td>Day 106 responses</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0003</td>
<td>Day 180 responses</td>
<td>maa</td>
<td>0000</td>
<td>response</td>
</tr>
<tr>
<td>0004</td>
<td>Day 210 Agreed English product</td>
<td>maa</td>
<td>0000</td>
<td>response*</td>
</tr>
<tr>
<td></td>
<td>information</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0005</td>
<td>consolidation after closure of procedure</td>
<td>maa</td>
<td>0000</td>
<td>consolidating**</td>
</tr>
</tbody>
</table>

* If only the final product information text version is necessary to be submitted the submission unit type 'closing' should be chosen.
** In case not all outstanding consolidation has been done by sequence 0004 this additional sequence 0005 is required.

Table 3: Example of a Variation

<table>
<thead>
<tr>
<th>Sequence number</th>
<th>Submission Description</th>
<th>Submission Type</th>
<th>Related Sequence</th>
<th>Submission Unit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0008</td>
<td>Variation for new indication of COPD</td>
<td>var-type2</td>
<td>0008</td>
<td>none</td>
</tr>
<tr>
<td>0009</td>
<td>Validation update</td>
<td>var-type2</td>
<td>0008</td>
<td>validation-response</td>
</tr>
<tr>
<td>0010</td>
<td>Responses to questions</td>
<td>var-type2</td>
<td>0008</td>
<td>response</td>
</tr>
</tbody>
</table>
Example of the use of the submission type ‘referral-31’

Referrals according to article 31 are covering in many cases applications from different procedures. So the completing of metadata seems to be difficult and causes inconsistencies. The eCTD envelope will reflect the products involved. For a pharmacovigilance issue impacting multiple products the referral is run as a centralised procedure. The envelope should indicate the referral procedure number as well as the MR/DC procedure number the submitted sequence relates to.

**Envelope for EMA**

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UUID</td>
<td>c3ac0ae6-f07e-4ead-8f35-403429361d5b</td>
</tr>
<tr>
<td>Submission Type</td>
<td>Referral-31</td>
</tr>
<tr>
<td>Submission Mode</td>
<td>worksharing</td>
</tr>
<tr>
<td>Number</td>
<td>EMEA/H/A-31/9999</td>
</tr>
<tr>
<td>Procedure-Tracking Number(s):</td>
<td>PT/H/9999/001-002</td>
</tr>
<tr>
<td>Submission Unit Type</td>
<td>initial</td>
</tr>
<tr>
<td>Applicant</td>
<td>Miracle Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>Agency</td>
<td>EMA - European Medicines Agency (EU-EMA)</td>
</tr>
<tr>
<td>Procedure</td>
<td>Centralised Procedure</td>
</tr>
<tr>
<td>Invented Name</td>
<td>Ibuprofen referral</td>
</tr>
<tr>
<td>INN</td>
<td>Ibuprofen</td>
</tr>
<tr>
<td>Sequence</td>
<td>0000</td>
</tr>
<tr>
<td>Related-Sequence</td>
<td>0000</td>
</tr>
<tr>
<td>Submission Description</td>
<td>Referral under Article 31 evaluating hemorrhagia risk</td>
</tr>
</tbody>
</table>

In case of only one product concerned (but authorised on the European level) the submission mode will turn to single and the submission number will not be filled. The procedure type will also remain MRP and the sequence number must reflect the next free number:

**Envelope for CZ**

<table>
<thead>
<tr>
<th>Field</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>UUID</td>
<td>111954d7-a702-46b0-bc6b-483a38a63d50</td>
</tr>
<tr>
<td>Submission Type</td>
<td>Referral-31</td>
</tr>
<tr>
<td>Submission Mode</td>
<td>single</td>
</tr>
<tr>
<td>Number</td>
<td>PT/H/9999/001-002</td>
</tr>
<tr>
<td>Submission Unit Type</td>
<td>initial</td>
</tr>
<tr>
<td>Applicant</td>
<td>Miracle Pharmaceuticals, Inc.</td>
</tr>
</tbody>
</table>
Example of the use of the submission unit type ‘reformat’

The submission unit type ‘reformat’ should be used for each baseline submission. (Note: the submission unit type ‘additional-info’ should not be used for the second reformat submission.) Related sequence should be equal to the sequence number.

An example is given below.

<table>
<thead>
<tr>
<th>Sequence number</th>
<th>Submission Description</th>
<th>Submission Type</th>
<th>Related Sequence</th>
<th>Submission Unit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0000</td>
<td>Baseline of Modules 4 &amp; 5</td>
<td>none</td>
<td>0000</td>
<td>reformat</td>
</tr>
<tr>
<td>0001</td>
<td>Variation for new indication of COPD</td>
<td>var-type2</td>
<td>0001</td>
<td>initial</td>
</tr>
<tr>
<td>0002</td>
<td>Baseline of Module 3</td>
<td>none</td>
<td>0002</td>
<td>reformat</td>
</tr>
<tr>
<td>0003</td>
<td>Extension for 8mg tablet</td>
<td>extension</td>
<td>0003</td>
<td>initial</td>
</tr>
</tbody>
</table>

Example of how to use the submission type ‘withdrawal’ and how to indicate the withdrawal of a single regulatory activity or a strength or pharmaceutical form

If a variation needs to be withdrawn the sequence needs to re-establish the previous status of the dossier. Submitted documents justifying the variation need to be deleted or replaced by the previous version of a document. Therefore, the submission unit type of that sequence is ‘consolidating’. The submission description should state the intention of withdrawing the variation number (sequence 0007 from first example above). The related sequence points to the sequence number used for the initial submission of the variation as mentioned.

In case a strength or form will be withdrawn (but not the entire product) a new sequence must be created to delete from the dossier all documents that are no longer valid. Although this sequence will consolidate the dossier, the withdrawal of a strength is a variation and need to be handled as a new regulatory activity.
<table>
<thead>
<tr>
<th>Sequence number</th>
<th>Submission Description</th>
<th>Submission Type</th>
<th>Related Sequence</th>
<th>Submission Unit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0011</td>
<td>Withdrawal of variation to change manufacturing site 'Westferry'</td>
<td>var-type2</td>
<td>0007</td>
<td>consolidating</td>
</tr>
<tr>
<td>0012</td>
<td>Variation for new indication of back pain</td>
<td>var-type2</td>
<td>0012</td>
<td>response</td>
</tr>
<tr>
<td>0013</td>
<td>Response to clinical questions</td>
<td>var-type2</td>
<td>0012</td>
<td>closing</td>
</tr>
<tr>
<td>0014</td>
<td>Final product information texts</td>
<td>var-type2</td>
<td>0012</td>
<td></td>
</tr>
<tr>
<td>0015</td>
<td>Withdrawal of strength 200 mg</td>
<td>var-type1b</td>
<td>0015</td>
<td>initial</td>
</tr>
</tbody>
</table>

In case of withdrawing the entire application the sequence need to state this in a simple way (using submission description text field). This is considered as a regulatory activity, the submission type is ‘withdrawal’, the submission unit type ‘initial’ and the related sequence will be identical with the sequence number.

<table>
<thead>
<tr>
<th>Sequence number</th>
<th>Submission Description</th>
<th>Submission Type</th>
<th>Related Sequence</th>
<th>Submission Unit Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>0016</td>
<td>Withdrawal of the application (entirely)</td>
<td>withdrawal</td>
<td>0016</td>
<td>initial</td>
</tr>
</tbody>
</table>

### Appendix 1.2: Country-Specific Elements

A number of the elements that represent NtA Module 1 TOC headings possess the child element “specific”, which allows country-specificity of content to be explicitly indicated.

<table>
<thead>
<tr>
<th>Element</th>
<th>Attribute</th>
<th>Description/Instructions</th>
<th>Example</th>
<th>Constraint</th>
<th>Occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>specific</td>
<td>country</td>
<td>Parent element for identifying the receiving country for a document or documents.</td>
<td>N/A</td>
<td>Mandatory</td>
<td>Repeatable</td>
</tr>
<tr>
<td></td>
<td>country</td>
<td>The receiving country for the document(s) (or &quot;common&quot;) (see Appendix 2.1 for full list of allowable values)</td>
<td>uk</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
</tbody>
</table>

Module 1 elements that have “specific” child elements can therefore contain multiple documents, each with content for review by a different country. These elements are listed below:

- **m1-0-cover**  
  (1.0 Cover Letter)
- **m1-2-form**  
  (1.2 Application Form)
- **m1-3-2-mockup**  
  (1.3.2 Mock-Up)
- **m1-3-3-specimen**  
  (1.3.3 Specimen)
- **m1-3-4-consultation**  
  (1.3.4 Consultation with Target Patient Groups)
Appendix 1.3: Product Information Element Description

The "m1-3-1-spc-label-pl" corresponds to the Notice to Applicants heading 1.3.1 SPC, Labelling and Package Leaflet. This element can have multiple child "pi-doc" elements that allow identification of product information language, document type and applicable country as described below.

<table>
<thead>
<tr>
<th>Element</th>
<th>Attribute</th>
<th>Description/Instructions</th>
<th>Example</th>
<th>Constraint</th>
<th>Occurrence</th>
</tr>
</thead>
<tbody>
<tr>
<td>pi-doc</td>
<td></td>
<td>Parent element for identification of the type, language and country of one or more product information documents.</td>
<td>N/A</td>
<td>Mandatory</td>
<td>Repeatable</td>
</tr>
<tr>
<td></td>
<td>xml:lang</td>
<td>The language that the product information is written in (see Appendix 2.2 for allowable values).</td>
<td>fr</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td></td>
<td>type</td>
<td>The type of product information document (see Appendix 2.3 for allowable values).</td>
<td>combined</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
<tr>
<td></td>
<td>country</td>
<td>The receiving country for the product information (or &quot;common&quot;) (see Appendix 2.1 for full list of allowable values)</td>
<td>be</td>
<td>Mandatory</td>
<td>Unique</td>
</tr>
</tbody>
</table>
Appendix 2: Directory / File Structure for Module 1

The directory / file structure is defined in this appendix as a table containing the following information:

<table>
<thead>
<tr>
<th>Sequential number</th>
<th>Each item in the table has a unique sequentially assigned reference number. These reference numbers can change with each version of this appendix.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>CTD section number</td>
</tr>
<tr>
<td>Title</td>
<td>CTD title</td>
</tr>
<tr>
<td>Element</td>
<td>Element name in the EU Backbone</td>
</tr>
<tr>
<td>File/Directory</td>
<td>File/Directory name from m1/eu – should be relative path from eu/m1 e.g. 12-form/fr-form.pdf. This is consistent with ICH standards. The file extension corresponds to the file type; i.e. the “pdf” extension is only illustrative.</td>
</tr>
<tr>
<td>Comment</td>
<td>Comments</td>
</tr>
</tbody>
</table>

Where the following conventions are used:

<table>
<thead>
<tr>
<th>Codes*</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>CC</td>
<td>Country Code, also referred to as the destination code as per Appendix 2.1</td>
</tr>
<tr>
<td>LL</td>
<td>Local Language code as per Appendix 2.2</td>
</tr>
<tr>
<td>EXT</td>
<td>File extension.</td>
</tr>
<tr>
<td>PIDOC</td>
<td>Product Information Document identifier as per Appendix 2.3</td>
</tr>
<tr>
<td>VAR</td>
<td>Variable component of the filename.</td>
</tr>
<tr>
<td>DDDD</td>
<td>A sequence number made of 4 digits (e.g. 0000)</td>
</tr>
</tbody>
</table>

* = The names of the actual files and directories used should be presented in lower case in accordance with the eCTD specification. The use of upper case for codes is for illustrative purposes only to show differentiation between the variable parts and the fixed part of the name.
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Element</th>
<th>Directory</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Module 1 EU</td>
<td>m1-eu</td>
<td>m1/eu</td>
<td>Top level directory for the EU Module 1 as per ICH eCTD Specification</td>
</tr>
<tr>
<td>2</td>
<td></td>
<td></td>
<td></td>
<td>File m1/eu/eu-regional.xml</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comment The EU Regional XML instance including the envelope information. Note that the operation attribute for the eu.regional.xml should always be set to 'new'.</td>
</tr>
<tr>
<td>3</td>
<td>1.0</td>
<td></td>
<td></td>
<td>Title Cover Letter</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Element m1-0-cover</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Directory m1/eu/10-cover</td>
</tr>
<tr>
<td>4</td>
<td></td>
<td></td>
<td></td>
<td>Title</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Element</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Directory m1/eu/10-cover/CC</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comment Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>File</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>5</td>
<td></td>
<td></td>
<td>m1/eu/10-cover/CC/CC-cover-VAR.EXT</td>
<td>Filename for the Cover Letter composed of a fixed component “CC”, a fixed component “cover” and an optional variable component if required (e.g. fr-cover-variationrationale.pdf). When only the cover letter is submitted in this directory the file name should be CC-cover.pdf. Single document correspondences e.g. Letter of Undertakings should be placed here.</td>
</tr>
</tbody>
</table>
| 6      |       |         | m1/eu/10-cover/CC/CC-tracking-VAR.EXT | Note that the tracking table required with MPR/DCP submissions should be located within a 'common' directory, with the filename 'common-tracking-var.pdf'
In case of submissions of other procedure types the respective country code should be used, e.g. ema-tracking-var.pdf in case of a centralised procedure or de-tracking-var.pdf in case of a national procedure with BfArM or PEI. |
<p>| 7      | 1.2   | Application Form | m1-2-form | The Application Form refers to any form (new applications, applications for variations or renewals). |
| 8      |       |         | m1/eu/12-form/CC | Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission. |
| 9      |       |         |         | |</p>
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Element</th>
<th>Directory</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>10</td>
<td>1.3</td>
<td>Product Information</td>
<td>m1/eu/13-pi</td>
<td>General placeholder for Product Information</td>
</tr>
<tr>
<td>11</td>
<td>1.3.1</td>
<td>SmPC, Labelling and Package Leaflet</td>
<td>m1/eu/13-pi/131-spc-label-pl</td>
<td>General placeholder for SmPC, Labelling, Package Leaflet or Combined PI</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td></td>
<td>m1/eu/13-pi/131-spc-labelpl/CC</td>
<td>Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td>13</td>
<td></td>
<td></td>
<td>m1/eu/13-pi/131-spc-labelpl/CC</td>
<td>Always use a language directory at this level during the lifecycle of the submission. See Row 13 for an example.</td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>File</td>
</tr>
<tr>
<td>---</td>
<td>--------</td>
<td>---------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
<td></td>
<td>m1/eu/13-pl/131-spclabelpl/CC/CC-PIDOC-VAR.EXT</td>
</tr>
<tr>
<td>15</td>
<td></td>
<td>1.3.2</td>
<td>Mock-up</td>
<td>m1-3-2-mockup</td>
</tr>
<tr>
<td>16</td>
<td></td>
<td></td>
<td></td>
<td>m1/eu/13-pl/132-mockup/CC</td>
</tr>
<tr>
<td>17</td>
<td></td>
<td></td>
<td></td>
<td>m1/eu/13-pl/132-mockup/CC/CC-mockup-VAR.EXT</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>Directory</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>18</td>
<td>1.3.3</td>
<td>Specimen</td>
<td>m1-3-3-specimen</td>
<td>m1/eu/13-pi/133-specimen</td>
</tr>
<tr>
<td>19</td>
<td>1.3.3</td>
<td>Specimen</td>
<td>m1/eu/13-pi/133-specimen/CC</td>
<td>Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td>20</td>
<td>1.3.4</td>
<td>Consultation with Target Patient Groups</td>
<td>m1/eu/13-pi/134-consultation</td>
<td>Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td>21</td>
<td>1.3.4</td>
<td>Consultation with Target Patient Groups</td>
<td>m1/eu/13-pi/134-consultation</td>
<td>Filename for the list of physical specimens provided with the submission composed by a fixed component &quot;CC&quot;, a fixed component &quot;specimen&quot; and an optional variable component to be used if needed. (e.g. fr-specimen.pdf).</td>
</tr>
<tr>
<td>22</td>
<td>1.3.4</td>
<td>Consultation with Target Patient Groups</td>
<td>m1/eu/13-pi/134-consultation/CC</td>
<td>Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td></td>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>File</td>
</tr>
<tr>
<td>---</td>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>------</td>
</tr>
<tr>
<td>23</td>
<td></td>
<td></td>
<td></td>
<td>m1/eu/13-pi/134-consultation/CC/CC-consultation-VAR.EXT</td>
</tr>
<tr>
<td>24</td>
<td>1.3.5</td>
<td></td>
<td></td>
<td>m1-3-5-approved</td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
<td></td>
<td>m1/eu/13-pi/135-approved/CC</td>
</tr>
<tr>
<td>26</td>
<td></td>
<td></td>
<td></td>
<td>m1/eu/13-pi/135-approved/CC/CC-approved-VAR.EXT</td>
</tr>
<tr>
<td>27</td>
<td>1.3.6</td>
<td></td>
<td></td>
<td>m1-3-6-braille</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>Directory</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------</td>
<td>-------------------------------</td>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 28     |                                |                               |                    | 36 Number 28  
Title  Element  
File  m1/eu/13-pi/136-braille/braille-VAR.EXT  
Comment  File name for the Braille information is composed by a fixed component “braille” and an optional variable component to be used if needed. (e.g. braille.pdf). |
| 29     | Number 1.4                     | Information about the Experts | m1-4-expert        | 29 Number 29  
Title  Element  Directory  Comment  
Info about the Experts  m1-4-expert  m1/eu/14-expert  General placeholder for Expert Information. |
| 30     | Number 1.4.1                    | Quality                       | m1-4-1-quality     | 30 Number 30  
Title  Element  Directory  Comment  
Quality  m1-4-1-quality  m1/eu/14-expert/141-quality  General placeholder for quality information. |
| 31     | Number 1.4.2                    | Non-Clinical                  | m1-4-2-non-clinical| 31 Number 31  
Title  Element  Directory  Comment  
Non-Clinical  m1-4-2-non-clinical  m1/eu/14-expert/142-nonclinical  General placeholder for non-clinical information. |
| 32     |                                |                               |                    | 32 Number 32  
Title  Element  Directory  Comment  
Non-Clinical  m1-4-2-non-clinical  m1/eu/14-expert/142-nonclinical  General placeholder for non-clinical information. |
<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Element</th>
<th>File</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>33</td>
<td>Number</td>
<td>1.4.3</td>
<td>Clinical</td>
<td>m1/eu/14-expert/143-clinical</td>
</tr>
<tr>
<td>34</td>
<td>Number</td>
<td>1.4.3</td>
<td>Clinical</td>
<td>m1/eu/14-expert/143-clinical</td>
</tr>
<tr>
<td>35</td>
<td>Number</td>
<td>1.5</td>
<td>Specific Requirements for Different Types of Applications</td>
<td>m1/eu/15-specific</td>
</tr>
<tr>
<td>36</td>
<td>Number</td>
<td>1.5.1</td>
<td>Information for Bibliographical Applications</td>
<td>m1/eu/15-specific/151-bibliographic</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>File</td>
<td>m1/eu/15-specific/151-bibliographic/bibliographic-VAR.EXT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment</td>
<td>Filename for the specific bibliographic submission information composed by a fixed component “bibliographic” and an optional variable component to be used if needed. (e.g. bibliographic.pdf).</td>
<td></td>
</tr>
<tr>
<td>39</td>
<td>Number</td>
<td>1.5.2</td>
<td>Title</td>
<td>Information for Generic, ‘Hybrid’ or Bio-similar Applications</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Element</td>
<td>m1-5-2-generic-hybrid-biosimilar</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Directory</td>
<td>m1/eu/15-specific/152-generic-hybrid-bio-similar</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment</td>
<td>General placeholder for generic, ‘hybrid’ or bio-similar applications.</td>
<td></td>
</tr>
<tr>
<td>40</td>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>File</td>
<td>m1/eu/15-specific/152-generic-hybrid-bio-similar/generic-VAR.EXT or m1/eu/15-specific/152-generic-hybrid-bio-similar/hybrid-VAR.EXT or m1/eu/15-specific/152-generic-hybrid-bio-similar/biosimilar-VAR.EXT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment</td>
<td>Filename for the specific generic, hybrid or bio-similar submission information composed by a fixed component “generic” or “hybrid” or “biosimilar”, and an optional variable component to be used if needed (e.g. generic.pdf).</td>
<td></td>
</tr>
<tr>
<td>41</td>
<td>Number</td>
<td>1.5.3</td>
<td>Title</td>
<td>(Extended) Data/Market Exclusivity</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Element</td>
<td>m1-5-3-data-market-exclusivity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Directory</td>
<td>m1/eu/15-specific/153-data-market-exclusivity</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment</td>
<td>General placeholder for (extended) data/market exclusivity.</td>
<td></td>
</tr>
<tr>
<td>42</td>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>File</td>
<td>m1/eu/15-specific/153-data-market-exclusivity/datamarketexclusivity-VAR.EXT</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Comment</td>
<td>Filename for the data / market exclusivity composed of a fixed component “datamarketexclusivity” and an optional variable component to be used if needed (e.g. datamarketexclusivity.pdf).</td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>Directory</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>1.5.4</td>
<td>Exceptional Circumstances</td>
<td>m1-5-4-exceptional-circumstances</td>
<td>m1/eu/15-specific/154-exceptional</td>
<td>General placeholder for marketing authorisation granted under exceptional circumstances.</td>
</tr>
<tr>
<td>1.5.5</td>
<td>Conditional Marketing Authorisation</td>
<td>m1-5-5-conditional-ma</td>
<td>m1/eu/15-specific/155-conditional-ma</td>
<td>General placeholder for conditional marketing authorisation.</td>
</tr>
<tr>
<td>1.6</td>
<td>Environmental Risk Assessment</td>
<td>m1-6-environrisk</td>
<td>m1/eu/16-environrisk</td>
<td>General placeholder for Environmental Risk Assessment.</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>Directory</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>48</td>
<td>Non-GMO</td>
<td>m1-6-1-non-gmo</td>
<td>m1/eu/16-environrisk/161-nongmo</td>
<td>General placeholder for non-GMO.</td>
</tr>
<tr>
<td>49</td>
<td></td>
<td></td>
<td></td>
<td>Filename for the environmental risk assessment non-GMO composed by a fixed component “nongmo” and an optional variable component to be used if needed (e.g. nongmo.pdf).</td>
</tr>
<tr>
<td>50</td>
<td>GMO</td>
<td>m1-6-2-gmo</td>
<td>m1/eu/16-environrisk/162-gmo</td>
<td>General placeholder for GMO.</td>
</tr>
<tr>
<td>51</td>
<td></td>
<td></td>
<td></td>
<td>Filename for the environmental risk assessment GMO-composed by a fixed component “gmo” and an optional variable component to be used if needed (e.g. gmo.pdf).</td>
</tr>
<tr>
<td>52</td>
<td>Information relating to Orphan Market Exclusivity</td>
<td>m1-7-orphan</td>
<td>m1/eu/17-orphan</td>
<td>General placeholder for Orphan Market Exclusivity information.</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>Directory</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>53</td>
<td>1.7.1</td>
<td>Similarity</td>
<td>m1-7-1-similarity</td>
<td>General placeholder for information on similarity with authorised orphan product.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/17-orphan/171-similarity</td>
<td></td>
</tr>
<tr>
<td>54</td>
<td></td>
<td></td>
<td>m1/eu/17-orphan/171-similarity/similarity-VAR.EXT</td>
<td>Filename for the information on similarity composed by a fixed component “similarity” and an optional variable component to be used if needed.</td>
</tr>
<tr>
<td>55</td>
<td>1.7.2</td>
<td>Market Exclusivity</td>
<td>m1-7-2-market-exclusivity</td>
<td>General placeholder for information on market exclusivity.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/17-orphan/172-market-exclusivity</td>
<td></td>
</tr>
<tr>
<td>56</td>
<td></td>
<td></td>
<td>m1/eu/17-orphan/172-market-exclusivity/marketexclusivity-VAR.EXT</td>
<td>Filename for information on market exclusivity composed by a fixed component “marketexclusivity” and an optional variable component to be used if needed.</td>
</tr>
<tr>
<td>57</td>
<td>1.8</td>
<td>Information relating to Pharmacovigilance</td>
<td>m1-8-pharmacovigilance</td>
<td>General placeholder for information on pharmacovigilance.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/18-pharmacovigilance</td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>Directory</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>-----------</td>
<td>---------</td>
</tr>
<tr>
<td>58</td>
<td>1.8.1</td>
<td>Pharmacovigilance System</td>
<td>m1-8-1-pharmacovigilance-system</td>
<td>General placeholder for information on pharmacovigilance system.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/18-pharmacovigilance/181-phvig-system</td>
<td></td>
</tr>
<tr>
<td>59</td>
<td></td>
<td></td>
<td></td>
<td>Filename for information on pharmacovigilance system composed by a fixed component &quot;phvigsystem&quot; and an optional variable component to be used if needed.</td>
</tr>
<tr>
<td>60</td>
<td>1.8.2</td>
<td>Risk-management System</td>
<td>m1-8-2-risk-management-system</td>
<td>General placeholder for information on risk management system.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/18-pharmacovigilance/182-riskmgt-system</td>
<td></td>
</tr>
<tr>
<td>61</td>
<td></td>
<td></td>
<td></td>
<td>Filename for information on pharmacovigilance system composed by a fixed component &quot;riskmgtsystem&quot; and an optional variable component to be used if needed.</td>
</tr>
<tr>
<td>62</td>
<td>1.9</td>
<td>Information relating to Clinical Trials</td>
<td>m1-9-clinical-trials</td>
<td>General placeholder for information on clinical trials.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/19-clinical-trials</td>
<td></td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>File</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>63</td>
<td></td>
<td></td>
<td>m1/eu/19-clinical-trials/clinicaltrials-VAR.EXT</td>
<td>Filename for information on clinical trials composed by a fixed component “clinicaltrials” and an optional variable component to be used if needed.</td>
</tr>
<tr>
<td>64</td>
<td>1.10</td>
<td></td>
<td>m1-10-paediatrics</td>
<td>Information relating to Paediatrics</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/110-paediatrics</td>
<td>General placeholder for information on paediatrics.</td>
</tr>
<tr>
<td>65</td>
<td></td>
<td></td>
<td>m1/eu/110-paediatrics/paediatrics-VAR.EXT</td>
<td>Filename for information on paediatrics composed by a fixed component “paediatrics” and an optional variable component to be used if needed.</td>
</tr>
<tr>
<td>66</td>
<td></td>
<td></td>
<td>m1-responses</td>
<td>Responses to Questions</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>m1/eu/responses</td>
<td></td>
</tr>
<tr>
<td>67</td>
<td></td>
<td></td>
<td>m1/eu/responses/CC</td>
<td>Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td>Element</td>
<td>File</td>
<td>Comment</td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
</tr>
<tr>
<td>68</td>
<td></td>
<td></td>
<td>m1/eu/responses/CC/CC-responses-VAR.EXT</td>
<td>Filename for responses to questions composed by a fixed component “CC”, a fixed component “responses” and an optional variable component to be used if needed (e.g. be-responses.pdf).</td>
</tr>
<tr>
<td>69</td>
<td></td>
<td></td>
<td>m1/additional-data</td>
<td>The 'Additional Data' section should only be used for information required for National, MR and Decentralised Procedures; it is therefore not generally applicable for the Centralised Procedure, other than for justifications for active substances.</td>
</tr>
<tr>
<td>70</td>
<td></td>
<td></td>
<td>m1/eu/additional-data/CC</td>
<td>Always use the country directory at this level for all procedures even when only one file is submitted to only one country during the lifecycle of the submission.</td>
</tr>
<tr>
<td>71</td>
<td></td>
<td></td>
<td>m1/eu/additional-data/CC/CC-additionaldata-VAR.EXT</td>
<td>Filename for additional information requested composed by a fixed component “CC”, a fixed component “additionaldata” and an optional variable component to be used if needed (e.g. be-additionaldata-yellowpink.pdf). Supporting data for variations should be not be placed in this section; wherever possible they should be placed in the relevant CTD section, primarily within Module 3 'Quality' and Module 1 (1.3.1) 'Summary of Product Characteristics, Labelling and Package Leaflet'. Where documents cannot be assigned to specific CTD-defined locations, then they should be attached to the 1.2 Application Form. The same approach should be used for renewals. Additionally see comments in row no 9. The 'Additional Data' section should only be used for information required for country specific information/documentation for National, MR and Decentralised Procedures; it is not applicable for the Centralised Procedure, other than for justifications for active substances.</td>
</tr>
<tr>
<td>Number</td>
<td>Title</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>72</td>
<td>Title</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Element</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directory</td>
<td>m1/eu/util</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comment</td>
<td>Additional folder to hold utility files used in EU Region only.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>73</td>
<td>Title</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Element</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directory</td>
<td>m1/eu/util/dtd</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comment</td>
<td>Additional folder to hold DTD files used in EU Region only.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>74</td>
<td>Title</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Element</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directory</td>
<td>util/dtd</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comment</td>
<td>ICH specified location for eCTD DTD files.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75</td>
<td>Title</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Element</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Directory</td>
<td>util/style</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Comment</td>
<td>ICH specified location for eCTD style-sheet files. The style-sheet to be used should be the most recent version, which is always published as part of the specification package for download. Note that the XML instance can only point to one style-sheet and that referencing a customised style-sheet will effectively prevent the agency using the official one. It is therefore recommended not to submit customised style-sheets.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
## Appendix 2.1: Destination Codes

In most cases the destination code is an ISO-3166-1-alpha-2 code usually called “country code” or “CC” in this specification.

<table>
<thead>
<tr>
<th>Code</th>
<th>Destination</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>at</td>
<td>Austria</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>be</td>
<td>Belgium</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>bg</td>
<td>Bulgaria</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>common</td>
<td>All countries</td>
<td>This is not an ISO code, but should be used to identify documents that are potentially applicable to all EU countries, irrespective of whether they are participating in the procedure or not</td>
</tr>
<tr>
<td>cy</td>
<td>Cyprus</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>cz</td>
<td>Czech Republic</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>de</td>
<td>Germany</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>dk</td>
<td>Denmark</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>edqm</td>
<td>EDQM</td>
<td>This is not an ISO code, but should be used as per guidance for application forms provided by EDQM</td>
</tr>
<tr>
<td>ee</td>
<td>Estonia</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>el</td>
<td>Greece</td>
<td>This is not an ISO code, but should be used as per guidance for application forms in the Notice to Applicants</td>
</tr>
<tr>
<td>ema</td>
<td>EMA</td>
<td>This is not an ISO code, but should be used for files that apply to all countries in the Centralised Procedure.</td>
</tr>
<tr>
<td>es</td>
<td>Spain</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>fi</td>
<td>Finland</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>fr</td>
<td>France</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>hr</td>
<td>Croatia</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>hu</td>
<td>Hungary</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>ie</td>
<td>Ireland</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>is</td>
<td>Iceland</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>it</td>
<td>Italy</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>li</td>
<td>Liechtenstein</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>lt</td>
<td>Lithuania</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>lu</td>
<td>Luxembourg</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>lv</td>
<td>Latvia</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>mt</td>
<td>Malta</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>nl</td>
<td>Netherlands</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>no</td>
<td>Norway</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>pl</td>
<td>Poland</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>pt</td>
<td>Portugal</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>ro</td>
<td>Romania</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>se</td>
<td>Sweden</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>si</td>
<td>Slovenia</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>sk</td>
<td>Slovakia</td>
<td>ISO-3166-1-alpha-2 code</td>
</tr>
<tr>
<td>uk</td>
<td>United Kingdom</td>
<td>This is not an ISO country code, but should be used as per guidance for application forms in the Notice to Applicants</td>
</tr>
</tbody>
</table>
### Appendix 2.2: Language Codes

<table>
<thead>
<tr>
<th>Code</th>
<th>Language</th>
</tr>
</thead>
<tbody>
<tr>
<td>bg</td>
<td>Bulgarian</td>
</tr>
<tr>
<td>cs</td>
<td>Czech</td>
</tr>
<tr>
<td>da</td>
<td>Danish</td>
</tr>
<tr>
<td>de</td>
<td>German</td>
</tr>
<tr>
<td>el</td>
<td>Greek</td>
</tr>
<tr>
<td>en</td>
<td>English</td>
</tr>
<tr>
<td>es</td>
<td>Spanish</td>
</tr>
<tr>
<td>et</td>
<td>Estonian</td>
</tr>
<tr>
<td>fi</td>
<td>Finnish</td>
</tr>
<tr>
<td>fr</td>
<td>French</td>
</tr>
<tr>
<td>hr</td>
<td>Croatian</td>
</tr>
<tr>
<td>hu</td>
<td>Hungarian</td>
</tr>
<tr>
<td>is</td>
<td>Icelandic</td>
</tr>
<tr>
<td>it</td>
<td>Italian</td>
</tr>
<tr>
<td>lt</td>
<td>Lithuanian</td>
</tr>
<tr>
<td>lv</td>
<td>Latvian</td>
</tr>
<tr>
<td>mt</td>
<td>Maltese</td>
</tr>
<tr>
<td>nl</td>
<td>Dutch</td>
</tr>
<tr>
<td>no</td>
<td>Norwegian</td>
</tr>
<tr>
<td>pl</td>
<td>Polish</td>
</tr>
<tr>
<td>pt</td>
<td>Portuguese</td>
</tr>
<tr>
<td>ro</td>
<td>Romanian</td>
</tr>
<tr>
<td>sk</td>
<td>Slovakian</td>
</tr>
<tr>
<td>sl</td>
<td>Slovenian</td>
</tr>
<tr>
<td>sv</td>
<td>Swedish</td>
</tr>
</tbody>
</table>

### Appendix 2.3: SPC, Labelling and Package Leaflet File Name Identifiers

<table>
<thead>
<tr>
<th>PI DOC</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>spc</td>
<td>Summary of Product Characteristics</td>
</tr>
<tr>
<td>annex2</td>
<td>Annex II</td>
</tr>
<tr>
<td>outer</td>
<td>Outer Packaging</td>
</tr>
<tr>
<td>interpack</td>
<td>Intermediate Packaging*</td>
</tr>
<tr>
<td>impack</td>
<td>Immediate Packaging</td>
</tr>
<tr>
<td>other</td>
<td>Other product information</td>
</tr>
<tr>
<td>pl</td>
<td>Package Leaflet</td>
</tr>
<tr>
<td>combined</td>
<td>Single text file incorporating the following documents: spc + annex2 + outer + interpack + impack + other + pl, in this sequence as applicable for the Centralised Procedure. Only one file per language is required. 'Combined' means presented as one document.</td>
</tr>
</tbody>
</table>

* = When labelling documents are submitted as a single file, the type ‘interpack’ should be used
Appendix 2.4: Agency Codes and Names

The table below provides the list of Agencies as identified on the Heads of Medicines Agency website, i.e. [http://www.hma.eu](http://www.hma.eu). The Agency Code is the value to use from within the EU Module 1 XML file.

<table>
<thead>
<tr>
<th>Country</th>
<th>Agency Code</th>
<th>Human/Vet (H/V)*</th>
<th>Agency Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Austria</td>
<td>AT-BASG</td>
<td>H/V</td>
<td>Austria - BASG-Austrian Federal Office for Safety in Health Care / Austrian Medicines and Medical Devices Agency</td>
</tr>
<tr>
<td>Belgium</td>
<td>BE-FAMHP</td>
<td>H/V</td>
<td>Belgium - Agence Fédérale des Médicaments et des Produits de Santé</td>
</tr>
<tr>
<td>Bulgaria</td>
<td>BG-BDA</td>
<td>H</td>
<td>Bulgaria - Bulgarian Drug Agency</td>
</tr>
<tr>
<td>Croatia</td>
<td>HR-HALMED</td>
<td>H</td>
<td>Croatia – Agency for Medicinal Products and Medical Devices of Croatia</td>
</tr>
<tr>
<td>Cyprus</td>
<td>CY-PHS</td>
<td>H/V</td>
<td>Cyprus - Pharmaceutical Services, Ministry of Health</td>
</tr>
<tr>
<td>Czech Rep.</td>
<td>CZ-SUKL</td>
<td>H</td>
<td>Czech Rep - State Institute for Drug Control</td>
</tr>
<tr>
<td>Denmark</td>
<td>DK-DKMA</td>
<td>H/V</td>
<td>Denmark - Danish Medicines Agency</td>
</tr>
<tr>
<td>Estonia</td>
<td>EE-SAM</td>
<td>H/V</td>
<td>Estonia - State Agency of Medicines</td>
</tr>
<tr>
<td>EU</td>
<td>EU-EDQM</td>
<td>H/V</td>
<td>EDQM – European Directorate for the Quality of Medicines &amp; HealthCare</td>
</tr>
<tr>
<td>EU</td>
<td>EU-EMA</td>
<td>H/V</td>
<td>EMA - European Medicines Agency</td>
</tr>
<tr>
<td>Finland</td>
<td>FI-FIMEA</td>
<td>H/V</td>
<td>Finland - Finnish Medicines Agency</td>
</tr>
<tr>
<td>France</td>
<td>FR-ANSM</td>
<td>H</td>
<td>France - ANSM - Agence nationale de sécurité du médicament et des produits de santé</td>
</tr>
<tr>
<td>Germany</td>
<td>DE-BFARM</td>
<td>H</td>
<td>Germany - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte</td>
</tr>
<tr>
<td>Germany</td>
<td>DE-PEI</td>
<td>H/V</td>
<td>Germany – PEI - Paul-Ehrlich Institut, Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel</td>
</tr>
<tr>
<td>Greece</td>
<td>EL-EOF</td>
<td>H/V</td>
<td>Greece - EOF - National Drug Organisation</td>
</tr>
<tr>
<td>Hungary</td>
<td>HU-OGYI</td>
<td>H</td>
<td>Hungary - National Institute of Pharmacy</td>
</tr>
<tr>
<td>Iceland</td>
<td>IS-IMCA</td>
<td>H/V</td>
<td>Iceland - Icelandic Medicines Control Agency</td>
</tr>
<tr>
<td>Ireland</td>
<td>IE-HPRA</td>
<td>H/V</td>
<td>Ireland - The Health Products Regulatory Authority</td>
</tr>
<tr>
<td>Italy</td>
<td>IT-AIFA</td>
<td>H</td>
<td>Italy - Agenzia Italiana del Farmaco</td>
</tr>
<tr>
<td>Latvia</td>
<td>LV-ZVA</td>
<td>H/V</td>
<td>Latvia - State Agency of Medicines</td>
</tr>
<tr>
<td>Country</td>
<td>Code</td>
<td>Type</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>------</td>
<td>------</td>
<td>-----------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Liechtenstein</td>
<td>LI-LLV</td>
<td>H/V</td>
<td>Liechtenstein - Kontrollstelle für Arzneimittel beim Amt für Lebensmittelkontrolle und Veterinärwesen</td>
</tr>
<tr>
<td>Lithuania</td>
<td>LT-SMCA</td>
<td>H</td>
<td>Lithuania - State Medicines Control Agency</td>
</tr>
<tr>
<td>Luxembourg</td>
<td>LU-MINSANT</td>
<td>H/V</td>
<td>Luxembourg - Direction de la Santé Villa Louvigny Division de la Pharmacie et des Medicaments</td>
</tr>
<tr>
<td>Malta</td>
<td>MT-MEDAUTH</td>
<td>H</td>
<td>Malta - Medicines Authority Divizjoni Tas-Sahha Bezzjoni Ghar-Regolazzjoni Tal-Medicini</td>
</tr>
<tr>
<td>Netherlands</td>
<td>NL-MEB</td>
<td>H/V</td>
<td>Netherlands - College ter Beoordeling van Geneesmiddelen Medicines Evaluation Board</td>
</tr>
<tr>
<td>Norway</td>
<td>NO-NOMA</td>
<td>H/V</td>
<td>Norway - The Norwegian Medicines Agency</td>
</tr>
<tr>
<td>Poland</td>
<td>PL-URPL</td>
<td>H/V</td>
<td>Poland - Office for Registration of Medicinal Products, Medical Devices and Biocidal Products</td>
</tr>
<tr>
<td>Portugal</td>
<td>PT-INFARMED</td>
<td>H/V</td>
<td>Portugal - INFARMED - Instituto Nacional da Farmácia e do Medicamento Parque da Saúde de Lisboa</td>
</tr>
<tr>
<td>Romania</td>
<td>RO-ANMMD</td>
<td>H/V</td>
<td>Romania - National Agency for Medicines and Medical Devices</td>
</tr>
<tr>
<td>Slovak Rep.</td>
<td>SK-SIDC</td>
<td>H</td>
<td>Slovak Rep - State Institute for Drug Control</td>
</tr>
<tr>
<td>Slovenia</td>
<td>SI-JAZMP</td>
<td>H/V</td>
<td>Slovenia - Javna agencija Republike Slovenije za zdravila in medicinske pripomočke</td>
</tr>
<tr>
<td>Spain</td>
<td>ES-AEMPS</td>
<td>H/V</td>
<td>Spain - Agencia Española de Medicamentos y Productos Sanitarios</td>
</tr>
<tr>
<td>Sweden</td>
<td>SE-MPA</td>
<td>H/V</td>
<td>Sweden - Medical Products Agency</td>
</tr>
<tr>
<td>United Kingdom</td>
<td>UK-MHRA</td>
<td>H</td>
<td>Medicines and Healthcare products Regulatory Agency</td>
</tr>
</tbody>
</table>

*eCTD apply only for Marketing Authorisation applications for medicinal products for human use.*
Appendix 3: Modularised DTD for EU Module 1
eu-regional.dtd

<!--
PUBLIC "-//EU//DTD eCTD EU Backbone 3.0//EN"
In the eCTD File Organisation: "util/dtd/eu-regional.dtd"

August 2009

Contributors:
  ANSM (Aziz Diop)
  EMA (Laurent Desqueper)
  MEB (C.A. van Belkum)

February 2013

Contributors:
  EMA (Antonios Yfantis)

June 2015

Contributors:
  BFARM (Klaus Menges)

Meaning or value of the suffixes:
  ? : element must appear 0 or 1 time
  * : element must appear 0 or more time
  + : element must appear 1 or more times
  <none>: element must appear once and only once
-->

<!-- General declarations, external modules references................. -->
<!ENTITY % countries "(at|be|bg|common|cy|cz|de|dk|edqm|ee|el|es|ema|fi|fr|hr|hu|ie|is|it|li|lt|lu|lv|mt|nl|no|pl|pt|ro|se|si|sk|uk)"
<!ENTITY % languages "(bg|cs|da|de|el|en|es|et|fi|fr|hr|hu|is|it|lt|lv|mt|nl|no|pl|pt|ro|sk|sl|sv)"

<!ENTITY % leaf-node "(( leaf | node-extension )*)">

<!ENTITY % envelope-module SYSTEM "eu-envelope.mod" >
%envelope-module;

<!ENTITY % leaf-module SYSTEM "eu-leaf.mod" >
%leaf-module;

<!ELEMENT specific (  
  %leaf-node;  
)>
<!ATTLIST specific  
  country %countries; #REQUIRED  
>
<!ELEMENT pi-doc (  
  %leaf-node;  
)>

51
<!--

-->

<!ELEMENT m1-3-pi (  
  m1-3-1-spc-label-pl?,  
  m1-3-2-mockup?,  
  m1-3-3-specimen?,  
  m1-3-4-consultation?,  
  m1-3-5-approved?,  
  m1-3-6-braille?)>

<!ELEMENT m1-3-1-spc-label-pl (  
  pi-doc+)>

<!ELEMENT m1-3-2-mockup (  
  specific+)>

<!ELEMENT m1-3-3-specimen (  
  specific+)>

<!ELEMENT m1-3-4-consultation (  
  specific+)>

<!ELEMENT m1-3-5-approved (  
  specific+)>

<!ELEMENT m1-3-6-braille (  
  %leaf-node;)
>

<!--

-->

<!ELEMENT m1-4-expert (  
  m1-4-1-quality?,  
  m1-4-2-non-clinical?,  
  m1-4-3-clinical?)>

<!ELEMENT m1-4-1-quality %leaf-node;>  
<!ELEMENT m1-4-2-non-clinical %leaf-node;>  
<!ELEMENT m1-4-3-clinical %leaf-node;>

<!--

-->

<!ELEMENT m1-5-specific (  
  m1-5-1-bibliographic?,  
  m1-5-2-generic-hybrid-bio-similar?,  
  m1-5-3-data-market-exclusivity?,  
  m1-5-4-exceptional-circumstances?,  
  m1-5-5-conditional-ma?)>
eu-envelope.mod

<!--
In the eCTD File Organisation: "util/dtd/eu-envelope.mod"

Version 1.4
February 2009
Contributors:
  ANSM (Aziz Diop)
  EMA (Laurent Desqueper)
  MEB (C.A. van Belkum)

Version 2.0
February 2013
Contributors:
  EMA (Antonios Yfantis)

Version 3.0
October 2015
Contributors:
  BFARM (Klaus Menges)
-->

<!ELEMENT eu-envelope ( envelope+)>

<!ELEMENT envelope ( identifier, submission, submission-unit, applicant, agency, procedure, invented-name+, inn*, sequence, related-sequence+, submission-description )>

<!ELEMENT identifier ( #PCDATA ) >
<!ELEMENT submission ( number?, procedure-tracking ) >
<!ELEMENT procedure-tracking ( number+ )>
<!--
........................................................................
-->
<!ENTITY % env-countries
"(at|be|bg|cy|cz|de|dk|edqm|ee|el|ema|es|fi|fr|hr|hu|ie|is|it|li|lt|
lu|lv|mt|nl|no|pl|pt|ro|se|si|sk|uk)">  

<!--
........................................................................
-->
<!ATTLIST envelope country %env-countries; #REQUIRED >

<!-- +++ -->
eu-leaf.mod

<!--
In the eCTD File Organisation: "util/dtd/eu-leaf.mod"

Version 1.4
August 2009

Contributors:
  ANSM (Aziz Diop)
  EMA (Laurent Desqueper)
  MEB (C.A. van Belkum)

This is based on ich-ectd-3-2.dtd;

If the ich-ectd.dtd is modularized, this one could be replaced. Hence, one is certain that the common and EU leaf are the same.
-->

<!-----------------------------------------------------------------
<!ELEMENT node-extension (title, (leaf | node-extension)+)>
<!ATTLIST node-extension
  ID ID #IMPLIED
  xml:lang CDATA #IMPLIED
>

<!-----------------------------------------------------------------
<!ENTITY % show-list " (new | replace | embed | other | none) ">
<!ENTITY % actuate-list " (onLoad | onRequest | other | none) ">
<!ENTITY % operation-list " (new | append | replace | delete) ">
<!ENTITY % leaf-element " (title, link-text?) ">
<!ENTITY % leaf-att '
  ID                  ID                #REQUIRED
  application-version CDATA             #IMPLIED
  version             CDATA             #IMPLIED
  font-library        CDATA             #IMPLIED
  operation           %operation-list;  #REQUIRED
  modified-file       CDATA             #IMPLIED
  checksum            CDATA             #REQUIRED
  checksum-type       CDATA             #REQUIRED
  keywords            CDATA             #IMPLIED
  xmlns:xlink         CDATA             #FIXED
"http://www.w3c.org/1999/xlink"
  xlink:type          CDATA             #FIXED    "simple"
  xlink:role          CDATA             #IMPLIED
  xlink:href          CDATA             #IMPLIED
  xlink:show         %show-list;       #IMPLIED
  xlink:actuate      %actuate-list;    #IMPLIED
  xml:lang           CDATA             #IMPLIED
'>

<!ELEMENT leaf %leaf-element;>
<!ATTLIST leaf